CXCR4 and glioblastoma: Likewise, CD133+ glioblastoma cancer stem cells with increased resistance to a range of chemotherapeutic agents, including paclitaxel, express high levels of CXCR4 [48], and high surface expression of this chemokine receptor is considered a marker of cancer stem cells [49].